首页|高流量氧疗配合无创呼吸通气治疗对重症肺炎伴呼吸衰竭患者的影响分析

高流量氧疗配合无创呼吸通气治疗对重症肺炎伴呼吸衰竭患者的影响分析

扫码查看
目的 探究高流量氧疗(high-flow nasal cannula oxygen therapy,HFNC)配合无创呼吸通气(non-invasive positive pressure ventilation,NIPPV)治疗对重症肺炎(severe pneumonia,SP)伴呼吸衰竭患者的影响.方法 回顾性选取2020年3月—2023年3月于淄博一四八医院接受治疗的120例SP伴呼吸衰竭患者临床资料,按治疗方案不同为对照组和观察组,各60例.观察组行HFNC配合NIPPV治疗,对照组行NIPPV治疗.比较两组患者临床疗效、动脉血气指标、炎症指标及不良反应发生情况.结果 治疗2周后,观察组患者治疗总有效率为96.67%(58/60),高于对照组的83.33%(50/60),差异有统计学意义(χ2=5.926,P=0.015).观察组患者治疗动脉血氧饱和度、血氧分压、酸碱度水平均高于对照组,动脉血二氧化碳分压低于对照组,差异有统计学意义(P均<0.05).观察组患者C-反应蛋白、白细胞介素-1、肿瘤坏死因子-α水平均低于对照组,差异有统计学意义(P均<0.05).观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05).结论 SP伴呼吸衰竭患者采用HFNC联合NIPPV治疗可提高临床疗效,能够改善动脉血气指标及炎症指标,且降低不良反应发生率.
Analysis of the Effect of High-flow Nasal Cannula Oxygen Therapy Com-bined with Non-invasive Respiratory Ventilation on Patients with Severe Pneumonia and Respiratory Failure
Objective To explore the effect of high-flow nasal cannula oxygen therapy(HFNC)combined with non-invasive positive pressure ventilation(NIPPV)on patients with severe pneumonia(SP)and respiratory failure.Meth-ods The clinical data of 120 SP patients with respiratory failure who were treated in Zibo 148 Hospital from March 2020 to March 2023 were retrospectively selected.According to the different treatment plans,they were divided into control group and observation group,with 60 cases in each group.The observation group was treated with HFNC com-bined with NIPPV,and the control group was treated with NIPPV.The clinical efficacy,arterial blood gas indexes,in-flammatory indexes and adverse reactions were compared between the two groups.Results After 2 weeks of treatment,the total effective rate of treatment in the observation group was 96.67%(58/60),which was higher than 83.33%(50/60)of the control group,and the difference was statistically significant(χ2=5.926,P=0.015).The levels of pulse oxy-gen saturation,partial pressure of oxygen and potential of hydrogen in the observation group were higher than those in the control group,and partial pressure of carbon dioxide in artery was lower than that in the control group,the differ-ence was statistically significant(all P<0.05).The levels of C-reactive protein,interleukin-1 and tumor necrosis fac-tor-α in the observation group were lower than those in the control group,and the differences were statistically signifi-cant(all P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion HFNC combined with NIPPV can improve the clinical efficacy of SP patients with respiratory failure,improve arterial blood gas indexes and inflammatory indexes,and reduce the incidence of adverse reactions.

Severe pneumoniaRespiratory failureHigh-flow nasal cannula oxygen therapyNon-invasive poshtiue pressure ventilationInflammatory markersArterial blood gas indicators

杨晓翠、高楠、刘超

展开 >

淄博一四八医院呼吸科,山东 淄博 255300

中国人民解放军联勤保障部队第九六〇医院呼吸科,山东 济南 250000

重症肺炎 呼吸衰竭 高流量氧疗 无创呼吸通气 炎症指标 动脉血气指标

2024

中外医疗
卫生部医院管理研究所 二十一世纪联合创新医药科学研究院

中外医疗

影响因子:0.909
ISSN:1674-0742
年,卷(期):2024.43(31)